Please go to the PowerPak homepage
and select a course.
Bringing Focus to Psoriatic Arthritis: Real-World Cases of Patient Needs and Pharmacist Interventions
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novartis Pharmaceuticals Corporation.
Jeannette Wick, RPh, MBA, FASCP
Assistant Director, Office of Pharmacy Professional Development and Visiting Instructor
University of Connecticut School of Pharmacy
Jeannette Wick, RPh, MBA, FASCP has no relevant affiliations or financial relationships with a commercial interest to disclose.
The following reviewer, Laura K. Stinson, PharmD, hereby states that she does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Susanne Batesko, RN, BSN, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 2.0 hour (0.2 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes
December 21, 2018
December 21, 2019
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period December 21, 2018 through December 21, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
The purpose of this activity is to use real-world patient examples to help pharmacists better understand the needs of patients with PsA. These cases will illustrate the problem of undiagnosed and undertreated PsA and will lead to better recognition of PsA and treatment of this condition. Pharmacists will gain knowledge regarding new treatment options with unique therapeutic targets for PsA with a focus on patient selection based on efficacy, safety, and administration. From the patient examples provided, pharmacists will also better recognize and understand reasons for treatment failure among these patients and current strategies for management when treatment failure does occur. Overall, pharmacists will be able to assess the treatment of patients with PsA and make recommendations for these patients that will increase their chances of successful treatment and improve their care.
Upon completion of this activity, participants should be better able to:
- Identify patients with psoriasis or joint pain who need to be screened for psoriatic arthritis
- Discuss treatment targets and satisfaction with psoriatic arthritis patients in efforts to assess the appropriateness of treatment regimens and identify undertreatment
- Examine new treatment options for psoriatic arthritis with unique mechanisms of action and be able to recommend these agents based on patient-specific characteristics
- Design treatment recommendations for patients with psoriatic arthritis who are not able to achieve goals with tumor necrosis factor– α inhibitors or who must discontinue agents based on tolerability
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Novartis Pharmaceuticals Corporation. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.